Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:BNTC
- CUSIP: N/A
- Web: www.benitec.com
- Market Cap: $20.22 million
- Outstanding Shares: 8,791,000
- 50 Day Moving Avg: $2.60
- 200 Day Moving Avg: $2.23
- 52 Week Range: $1.20 - $5.48
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.58
- P/E Growth: 0.00
- Annual Revenue: $7.22 million
- Price / Sales: 2.80
- Book Value: $1.58 per share
- Price / Book: 1.46
- Current Ratio: 21.89%
- Quick Ratio: 21.89%
- Average Volume: 409,823 shs.
- Beta: 2.53
- Short Ratio: 0.51
Frequently Asked Questions for Benitec Biopharma Ltd (NASDAQ:BNTC)
What is Benitec Biopharma Ltd's stock symbol?
Benitec Biopharma Ltd trades on the NASDAQ under the ticker symbol "BNTC."
Who are some of Benitec Biopharma Ltd's key competitors?
Some companies that are related to Benitec Biopharma Ltd include Trillium Therapeutics (TRIL), Histogenics Corp (HSGX), Chiasma (CHMA), Nivalis Therapeutics (NVLS), OHR Pharmaceutical (OHRP), KaloBios Pharmaceuticals (KBIO), Threshold Pharmaceuticals (THLD), Can Fite Biopharma Ltd (CANF), Alcobra Ltd (ADHD), Viking Therapeutics (VKTX), Mirna Therapeutics (MIRN), Ocera Therapeutics (OCRX), Catabasis Pharmaceuticals (CATB), Aldeyra Therapeutics (ALDX), Auris Medical Holding AG (EARS), Pain Therapeutics (PTIE), Dimension Therapeutics (DMTX) and Marinus Pharmaceuticals (MRNS).
When did Benitec Biopharma Ltd IPO?
(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.
How do I buy Benitec Biopharma Ltd stock?
Shares of Benitec Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Benitec Biopharma Ltd stock cost?
One share of Benitec Biopharma Ltd stock can currently be purchased for approximately $2.30.
Consensus Ratings for Benitec Biopharma Ltd (NASDAQ:BNTC) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Benitec Biopharma Ltd (NASDAQ:BNTC)
(Data available from 5/28/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|2/3/2017||Maxim Group||Reiterated Rating||Hold||N/A|
Earnings History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Benitec Biopharma Ltd (NASDAQ:BNTC)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.24 EPS
Dividend History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Benitec Biopharma Ltd (NASDAQ:BNTC)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Benitec Biopharma Ltd (NASDAQ:BNTC)
Latest Headlines for Benitec Biopharma Ltd (NASDAQ:BNTC)
Benitec Biopharma Ltd (BNTC) Chart for Sunday, May, 28, 2017